Construction method of immortalized human umbilical cord mesenchymal stem cells

By transfecting umbilical cord mesenchymal stem cells with lentiviral recombinant plasmid carrying the SV40 promoter, hTERT gene and EGFP gene, the problem of low transfection efficiency of human umbilical cord mesenchymal stem cells is solved, and long-term stable transfection and immortality of cells are achieved , providing a stable and multidirectional differentiation potential.

CN119060962AInactive Publication Date: 2024-12-03FIRST AFFILIATED HOSPITAL OF GANNAN MEDICAL UNIV

Patent Information

Application Number
CN202411479831.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-23
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to effectively immortalize human umbilical cord mesenchymal stem cells, especially in the process of gene transfer, and commonly used viral vectors such as adenovirus and retrovirus have problems with short expression time or difficulty in packaging.

Method used

Lentiviral recombinant plasmid carrying the SV40 promoter, hTERT gene and EGFP gene was used to package the virus by transfecting 293T cells and transfecting umbilical cord mesenchymal stem cells to achieve integration and long-term stable expression of hTERT gene and EGFP gene, and obtain green fluorescence Irreversible immortalized cells of proteins.

Benefits of technology

Long-term stable transfection and immortalization of human umbilical cord mesenchymal stem cells has been achieved, providing a tool for stable traits and good differentiation potential, and providing a convenient source of cellularity for gene therapy and cell therapy research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060962A_ABST
    Figure CN119060962A_ABST
Patent Text Reader

Abstract

The invention provides a construction method of immortalized human umbilical cord mesenchymal stem cells, and belongs to the technical field of immortalized cells, and the construction method comprises the following steps: firstly obtaining a human umbilical cord, digesting to obtain primary human umbilical cord mesenchymal stem cells, and carrying out subculture on the primary human umbilical cord mesenchymal stem cells; meanwhile, a lentivirus recombinant plasmid carrying an hTERT gene and an EGFP gene is synthesized, the lentivirus recombinant plasmid is packaged and transfected to prepare the umbilical cord mesenchymal stem cells, and the successfully transfected umbilical cord mesenchymal stem cells are screened; by utilizing the characteristics that a lentivirus system can transfect cells in a resting period, can be compatible with a plurality of transcription promoters and can maintain long-term and stable expression of an integrated exogenous gene, an hTERT gene and an EGFP gene are integrated into a human umbilical cord mesenchymal stem cell genome; the irreversibly immortalized human umbilical cord mesenchymal stem cells with the green fluorescent protein can be obtained, and a tool which is convenient and simple in source, stable in character and good in differentiation potential can be provided for research and clinical application of gene therapy, cell therapy and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of immortalized cells, and particularly relates to a method for constructing immortalized human umbilical cord mesenchymal stem cells. Background Art

[0002] Stem cells are cells with multidirectional differentiation potential, and have potential application value in gene therapy and cell therapy research. However, stem cells, like other normal cells in the body, will stop proliferating, age and die after a limited number of cell passages, i.e., cell senescence, which hinders the research on clinical application and mechanism of stem cells. Cell immortalization refers to the ability of cells to overcome the cell proliferation limit spontaneously or under the influence of external factors, and thus have the ability to proliferate indefinitely. If stem cells are immortalized to avoid the shortcomings of aging and disappearance of stemness during cell culture, and to maintain a multipotential differentiation state, it can not only provide stable characteristics for the study of stem cell biology, but also have potential application value in gene therapy, cell therapy and other research. For example, the invention patent with publication number: CN116855540A provides a method for immortalizing human bone marrow mesenchymal stem cells, which extracts bone marrow mesenchymal stem cells from human bone marrow, obtains immortalized bone marrow mesenchymal stem cells with multiple differentiation potentials after gene editing, screening and proliferation culture. However, extracting bone marrow mesenchymal stem cells from human bone marrow is technically difficult and costly, and can also cause harm to the human body.

[0003] The umbilical cord is a connecting structure between the fetus and the placenta, and is responsible for the material exchange between the fetus and the mother. After the fetus is born, the umbilical cord is generally treated as medical waste. If mesenchymal stem cells can be extracted from the umbilical cord, waste can be turned into treasure, but most of the human umbilical cord mesenchymal stem cells are in a quiescent state, so it is difficult to perform gene transfer on them. Currently commonly used gene transfer methods, such as various reagent transfection and electrotransfection, are relatively easy to transfect ordinary cell lines, but the transfection efficiency of human umbilical cord mesenchymal stem cells is very low. In recent years, the gradually developed viral vectors such as adenovirus and retrovirus have solved this problem to a certain extent, but there are still shortcomings, such as adenovirus is mostly transiently expressed after transfection, and the expression time is only a few days, which cannot meet the needs of long-term experimental observation in the research process of human umbilical cord mesenchymal stem cells. Retrovirus can achieve stable expression of exogenous genes in human umbilical cord mesenchymal stem cells, but retrovirus packaging is difficult, and the transfection efficiency of cells in the quiescent period is not high. Summary of the invention

[0004] Based on the above problems in the prior art, the present invention provides a method for constructing immortalized human umbilical cord mesenchymal stem cells, which first obtains human umbilical cord and digests it to obtain primary human umbilical cord mesenchymal stem cells, and then subcultures the primary human umbilical cord mesenchymal stem cells; at the same time, synthesizes a lentiviral recombinant plasmid carrying an SV40 promoter, an hTERT gene, and an EGFP gene, packages the lentiviral recombinant plasmid, and transfects the obtained umbilical cord mesenchymal stem cells, and screens the successfully transfected umbilical cord mesenchymal stem cells to obtain the finished product, which comprises the following detailed steps:

[0005] Step S1, obtaining a fresh umbilical cord under sterile conditions, removing the outer membrane and blood vessels, cleaning and cutting into small tissue blocks, cleaning again, sequentially performing a first trypsin digestion, type II collagenase digestion and a second trypsin digestion, centrifuging and discarding the supernatant, resuspending the precipitate in DMEM culture medium, filtering with a 200-mesh sieve, collecting the tissue blocks and the filtrate respectively, repeatedly performing type II collagenase and a second trypsin digestion on the tissue blocks for multiple times, collecting and mixing the filtrate obtained by multiple digestions to obtain primary human umbilical cord mesenchymal stem cell fluid, and performing primary culture and subculture;

[0006] Step S2, synthesizing a lentiviral recombinant plasmid carrying the SV40 promoter, hTERT gene and EGFP gene;

[0007] Step S3, culturing 293T cells, mixing Lipofectamine 2000, lentiviral recombinant plasmid and packaging plasmid, co-transfecting 293T cells, continuing to culture 293T cells after transfection and collecting virus liquid secreted by 293T cells, filtering by low-speed centrifugation to remove large particle impurities in the virus liquid, collecting virus precipitate by high-speed centrifugation, and resuspending the virus precipitate to obtain virus suspension;

[0008] Step S4, obtaining P3 generation umbilical cord mesenchymal stem cells from step S1, adding polybrene and the virus suspension prepared in step S3, continuing to culture the umbilical cord mesenchymal stem cells with DMEM low-glucose medium for transfection, and proliferating the transfected umbilical cord mesenchymal stem cells. When the proliferation culture reaches a cell density of more than 90%, adding a screening medium for screening culture, and the surviving cells after screening culture are the finished product.

[0009] Preferably, the lentiviral recombinant plasmid is pLV[Exp]-EF1A>hTERT-SV40>EGFP:T2A:Puro; the screening culture medium is a complete culture medium containing puromycin, and the concentration of puromycin is 0.4 μg / mL.

[0010] Preferably, the packaging plasmid includes pLP-VSVG plasmid and pPAX2 plasmid, and the mass ratio of pLP-VSVG plasmid, pPAX2 plasmid and lentiviral recombinant plasmid is 1:2:3.

[0011] Preferably, the cleaning in step S1 is performed by using phosphate buffered saline (PBS); the first trypsin digestion is to add 1.25 g / L trypsin to the small tissue block, digest it in a CO2 incubator for 20 minutes, and then add fetal bovine serum to terminate the digestion; the type II collagenase digestion is to add 0.075% type II collagenase at a volume ratio of 1:8, seal it and place it in a 37°C water bath for shaking and digesting for 1 hour; the second trypsin digestion is to add 1.25 g / L trypsin and digest it in a 37°C water bath for 30 minutes, shaking it once every 10 minutes.

[0012] Preferably, after the second trypsin digestion in step S1 is completed, centrifugation is performed at 1100 r / min for 10 min, the precipitate is washed with phosphate buffered saline (PBS) and then centrifuged at 1100 r / min for 10 min to separate the precipitate and the supernatant, and the precipitate is resuspended with low-glucose DMEM culture medium.

[0013] Preferably, in step S1, a DMEM culture medium containing 10% fetal bovine serum by volume is used, and the DMEM culture medium contains 100U / mL penicillin and 100U / mL streptomycin; the subculture is cultured in a CO2 incubator, the culture medium is changed every 3 days, and the cells are subcultured at a ratio of 1:3 after the cell density reaches 80%.

[0014] Preferably, in step S3, 293T cells are cultured until the cell density reaches 80-90% before transfection; the low-speed centrifugation filtration is first centrifuged at 1100 rpm for 5 minutes and then filtered with a 0.22 μm filter; the high-speed centrifugation is centrifuged at 25000 rpm and 4°C for 90 minutes.

[0015] Preferably, the specific operation of transfection in step S4 is to take umbilical cord mesenchymal stem cells and culture them in DMEM low-glucose medium for proliferation, count 5000 cells and then re-inoculate them into a 48-well culture plate at a seeding density of 5×10 4 cells / 100 μL / well, then add the virus suspension and polybrene to make the final concentration of 2 μg / mL for transfection. After transfection, centrifuge at 1100 r / min for 60 min at room temperature, take the precipitated cells and shake them evenly for proliferation culture.

[0016] The beneficial effects of the present invention are: utilizing the lentiviral system to transfect cells in a quiescent period, being compatible with multiple transcription promoters and being able to maintain the characteristics of long-term and stable expression of integrated exogenous genes, realizing the integration of hTERT gene and EGFP gene into the genome of human umbilical cord mesenchymal stem cells, obtaining irreversibly immortalized human umbilical cord mesenchymal stem cells with green fluorescent protein, and providing a tool with a convenient and simple source, stable properties and good differentiation potential for research and clinical applications such as gene therapy and cell therapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a map of the lentiviral recombinant plasmid pLV[Exp]-EF1A>hTERT-SV40>EGFP:T2A:Puro.

[0018] Figure 2 This is a comparison of the bright field and fluorescence images of transfected 293T cells under a X10x fluorescence microscope. Image A shows the morphology of 293T cells under bright field, and Image B shows 293T cells showing green fluorescence.

[0019] Figure 3 This is a comparison of the bright field and fluorescence images of transfected human umbilical cord mesenchymal stem cells under a X5x fluorescence microscope. Image A shows the cell state under bright field, and Image B shows the cells showing green fluorescence.

[0020] Figure 4 This is a result diagram of the gradient screening experiment of Example 2.

[0021] Figure 5 This is a diagram showing the results of identifying surface markers of normal human umbilical cord mesenchymal stem cells at passage 5 using flow cytometry in Example 3.

[0022] Figure 6 This is a diagram showing the results of identifying surface markers of immortalized human umbilical cord mesenchymal stem cells at passage 30 using flow cytometry in Example 3.

[0023] Figure 7 This is a graph showing the results of RT-PCR detection of hTERT gene expression in Example 4.

[0024] Figure 8 This is a diagram showing the results of the aging experiment in Example 5.

[0025] Fig. 9 This is a graph showing the results of the colony formation experiment in Example 6.

[0026] Fig.10 It is the result curve diagram in Example 7.

[0027] Fig.11 This is a diagram of the osteogenic induction experiment results in Example 8.

[0028] Fig.12 This is a diagram showing the results of the adipogenesis induction experiment in Example 9.

[0029] Fig.13 It is the soft agar plate experiment result figure in Example 10.

[0030] Fig.14 This is a diagram of the results of the cell karyotype analysis in Example 11.

[0031] in Figure 2 , Figure 3 , Figure 4 , Figure 8 , Fig. 9 , Fig.11 , Fig.12 and Fig.13 They are all experimental result pictures, some of which are images under a fluorescence microscope, and some are staining comparison pictures. In order to clearly display the experimental results, color pictures are needed for comparison.

[0032] In the sequence list:

[0033] SEQ ID 1 is the sequence of the lentiviral recombinant plasmid;

[0034] SEQ ID 2 is the hTERT-F (P11) primer sequence;

[0035] SEQ ID 3 is the hTERT-R (P12) primer sequence;

[0036] SEQ ID 4 is the GAPDH-F (P11) primer sequence;

[0037] SEQ ID 5 is the GAPDH-R (P11) primer sequence; DETAILED DESCRIPTION

[0038] The technical solution of the present invention is described below in conjunction with the accompanying drawings and specific embodiments.

[0039] Example 1: A method for constructing immortalized human umbilical cord mesenchymal stem cells.

[0040] The present embodiment provides a method for constructing immortalized human umbilical cord mesenchymal stem cells, which first obtains human umbilical cord and digests it to obtain primary human umbilical cord mesenchymal stem cells, and then subcultures the primary human umbilical cord mesenchymal stem cells; at the same time, synthesizes a lentiviral recombinant plasmid carrying an SV40 promoter, an hTERT gene, and an EGFP gene, packages the lentiviral recombinant plasmid, and transfects the obtained umbilical cord mesenchymal stem cells, and selects the successfully transfected umbilical cord mesenchymal stem cells, which are the finished products, and the method includes the following detailed steps:

[0041] Step S1, under sterile conditions, take a fresh umbilical cord obtained from a full-term normal delivery baby, peel off the umbilical cord outer membrane, remove the umbilical artery and vein, rinse it with phosphate buffered saline (PBS), cut it into tissue blocks of about 1mm×1mm×1mm, and then rinse it with phosphate buffered saline (PBS) for multiple times until the tissue blocks turn white; after cleaning, place the tissue blocks in a culture dish, add 1.25g / L trypsin, digest in a CO2 incubator for 20min, then add fetal bovine serum to terminate the digestion, centrifuge at 1100r / min for 4min, and discard the digestion solution containing the supernatant; then add 0.075% type II collagenase at a volume ratio of 1:8, seal it and place it in a 37°C water bath for shaking digestion for 1h, centrifuge it at 1100r / min for 4min, and discard the supernatant; then place the tissue blocks in 1.25g / L trypsin and digest them in a 37°C water bath for 30min, each The mixture was shaken once every 10 minutes, and then centrifuged at 1100 r / min for 10 minutes. The precipitate was washed with phosphate buffered saline (PBS) and then centrifuged at 1100 r / min for 10 minutes to separate the precipitate and the supernatant. The precipitate was resuspended in a low-glucose DMEM culture medium containing 10% fetal bovine serum by volume, and the DMEM culture medium contained 100 U / mL penicillin and 100 U / mL streptomycin. The suspension was filtered with a 200-mesh stainless steel sieve, and the tissue blocks and the filtrate were collected respectively. The tissue blocks were digested with type II collagenase and a second trypsin digestion were repeated 3 times, and the filtrates obtained by multiple digestions were collected and mixed to obtain the primary human umbilical cord mesenchymal stem cell liquid. The primary human umbilical cord mesenchymal stem cell liquid was inoculated into a sterile culture dish and subcultured in a CO2 incubator. The culture medium was changed every 3 days, and the cells were subcultured at a ratio of 1:3 after the cell density reached 80%.

[0042] Step S2, artificially synthesize the lentiviral recombinant plasmid pLV[Exp]-EF1A>hTERT-SV40>EGFP:T2A:Puro carrying the SV40 promoter, hTERT gene and EGFP gene. This step is commissioned to a commercial biological company for synthesis. The map of the lentiviral recombinant plasmid is shown in Figure 1 As shown;

[0043] Step S3, one day in advance, 293T cells were inoculated into a 100 mm culture dish containing culture medium for proliferation culture, and when the cell density reached 80-90%, transfection was performed using Lipofectamine2000-mediated transfection method. The packaging plasmid used in transfection was prepared by mixing pLP-VSVG plasmid and pPAX2 plasmid. The mass ratio of pLP-VSVG plasmid, pPAX2 plasmid and lentiviral recombinant plasmid was 1:2:3, and the total mass was 4 μg. The lentiviral recombinant plasmid, packaging plasmid and 40 μL of Lipofectamine2000 were first mixed, and then mixed with 1.5 mL of high glucose culture medium, cultured in a 37°C cell culture incubator, co-transfected 293T cells, and the transfected 293T cells were observed using a fluorescence microscope. The results are as follows Figure 2 As shown, most cells can be seen to express green fluorescence, indicating that the lentiviral expression vector and envelope plasmid have been successfully transfected into 293T cells and packaged into lentivirus that can express the corresponding protein. Continue to culture 293T cells, collect the virus liquid secreted by 293T cells at 24h and 48h of culture, first centrifuge at 1100rpm for 5min, filter the supernatant with a 0.22μm filter to remove large particles in the virus liquid, and then centrifuge at 25000rpm at 4℃ for 90min to collect the virus precipitate, resuspend the virus precipitate with 300μL serum-free stem cell culture medium to obtain the virus suspension, which can be used for virus titer detection or frozen at -80℃ after aliquoting;

[0044] Step S4, obtain P3 normal umbilical cord mesenchymal stem cells from step S1, culture them in DMEM low-glucose medium for 48 h for proliferation, count 5000 cells and re-inoculate them into a 48-well culture plate at a seeding density of 5×10 4 cells / 100 μL / well, then add the virus suspension, and add Polybrane to make the final concentration of 2 μg / mL, mix the virus suspension, Polybrane and umbilical cord mesenchymal stem cells for transfection, centrifuge at 1100 r / min for 60 min at room temperature after transfection, take the precipitated cells, shake them evenly, put them into the incubator and continue to culture for 24 hours, then replace the DMEM low-glucose medium for proliferation culture, and add the screening medium for screening culture when the proliferation culture reaches more than 90% of the cell density, wherein the screening medium is a complete medium containing puromycin, and the concentration of puromycin is 0.4 μg / mL, and the screening culture is carried out for 8 days until all the normal human umbilical cord mesenchymal stem cells that have not been successfully transfected die, and the surviving cells are the finished products, and the transfected umbilical cord mesenchymal stem cells are observed by fluorescence microscopy, and the results are as follows: Figure 3 As shown, it shows that the lentivirus successfully transfected human umbilical cord mesenchymal stem cells.

[0045] Example 2: Gradient screening experiment of puromycin concentration in screening culture medium.

[0046] The fifth generation of human umbilical cord mesenchymal stem cells were added to a 12-well plate, with 30,000 cells per well. The screening experiment was performed using low-glucose DMEM medium containing puromycin at concentrations of 0 μg / mL, 0.2 μg / mL, 0.4 μg / mL, 0.8 μg / mL, and 1.6 μg / mL. The corresponding concentration of puromycin medium was replaced every 3 days, and photos were taken every day for observation. Figure 4 As shown, from left to right, the low-glucose DMEM medium with 0μg / mL, 0.2μg / mL, 0.4μg / mL, 0.8μg / mL, and 1.6μg / mL puromycin was added. The results showed that all stem cells in the medium with 0.4μg / mL puromycin were dead on day 8. Therefore, the patent selected the lowest concentration of 0.4μg / mL puromycin that can kill all normal human umbilical cord mesenchymal stem cells on day 8.

[0047] Example 3: Identification of surface markers of immortalized human umbilical cord mesenchymal stem cells by flow cytometry.

[0048] Take the 5th generation normal human umbilical cord mesenchymal stem cells and the 30th generation immortalized human umbilical cord mesenchymal stem cells, wash them twice with PBS, add an appropriate amount of trypsin to digest for 30s-1min, and add serum-containing culture medium to terminate digestion when the cell morphology becomes round and shiny. Gently blow the cells to make them fall off, then transfer them to a centrifuge tube and centrifuge at 1100rmp / min for 4min, discard the supernatant, and wash them twice with an appropriate amount of PBS. The washed cells are filtered to make a single cell suspension, counted with a cell counting plate, and resuspended with PBS to 1×10 6 / mL cell suspension was first blocked with 1% BSA in the dark for 30 minutes, and then an appropriate amount of antibody was added according to the antibody instructions. After incubation at room temperature for 20 minutes, it was rinsed twice with PBS and then tested on a flow cytometer. The results were as follows Figure 5 and 6 As shown, the 5th generation normal human umbilical cord mesenchymal stem cells highly expressed cell surface marker antigens such as CD73, CD90, CD105, and CD44, and lowly expressed human umbilical cord mesenchymal stem cell surface marker antigens CD34 and CD45; the 30th generation immortalized human umbilical cord mesenchymal stem cells highly expressed cell surface marker antigens such as CD73, CD90, CD105, and lowly expressed human umbilical cord mesenchymal stem cell surface marker antigens CD34 and CD45.

[0049] Example 4: RT-PCR detection of hTERT gene expression.

[0050] The 5th generation normal human umbilical cord mesenchymal stem cells and the 30th generation hTERT overexpressed immortalized human umbilical cord mesenchymal stem cells were taken to extract total cell RNA, respectively. The hTERT gene was amplified using primers, and the hTERT mRNA expression level was detected using GAPDH as an internal reference. The primer sequences are as follows:

[0051] hTERT-F(P11): 5'-CGAAAACCTTCCTCAGGACC-3';

[0052] hTERT-R(P12): 5'-ACCACTGTCTTCCGCAAGTT-3';

[0053] GAPDH-F(P11): 5'-GAAGGTGAAGGTCGGAGTC-3';

[0054] GAPDH-R(P11): 5'-GAAGATGGGTGATGGGATTTC-3';

[0055] like Figure 7 As shown, the results of fluorescence quantitative PCR at the mRNA level showed that the mRNA expression level of hTERT gene in the 30th generation hTERT-overexpressing human umbilical cord mesenchymal stem cells was relatively high, which was about 157 times the expression level of hTERT gene in normal P5 generation human umbilical cord mesenchymal stem cells.

[0056] Example 5: Aging experiment of immortalized human umbilical cord mesenchymal stem cells.

[0057] Take the 5th generation normal human umbilical cord mesenchymal stem cells and the 30th generation immortalized human umbilical cord mesenchymal stem cells with good growth and 90% fusion, discard the culture medium, add appropriate amount of PBS to rinse the cells twice, remove PBS, add trypsin to completely cover the cells, digest for 30s-1min, and add serum-containing culture medium to terminate digestion when the cells become round and shiny. Transfer the digested cells to a centrifuge tube, centrifuge at 1100rmp / min for 4min, discard the supernatant, resuspend the cells with culture medium, and take appropriate amount of cells for counting.

[0058] 10,000 cells / well were inoculated into a six-well plate and cultured in a 37°C, 5% CO2 cell culture incubator for 14 days. The cells were taken out and washed twice with PBS, and β-galactosidase staining fixative was added. The cells were fixed at room temperature for 20 minutes, the fixative was discarded, and PBS was rinsed three times. β-galactosidase staining working solution was added. The six-well plate was sealed with plastic wrap, and incubated at 37°C overnight. The cells were observed and counted under a microscope the next day. The results were as follows. Figure 8 As shown in Figure 2, the manifestations of senescent cells are mainly enlargement, flattening, invagination of cell membrane, enlargement of nucleus, chromatin condensation, etc. Under the microscope, it can be seen that cells of the P30 generation ( Figure 8A) In terms of morphology, only a very small number of cells are senescent cells, and most cells are not senescent cells. ( Figure 8 B) It can be seen that the aging rate of normal human umbilical cord mesenchymal stem cells is much higher than that of immortalized human umbilical cord mesenchymal stem cells at the 30th generation. The proportion of blue cells (i.e. senescent cells) in 6 different fields of view is about 5%.

[0059] Example 6: Colony formation experiment of immortalized human umbilical cord mesenchymal stem cells.

[0060] Take the 5th generation normal human umbilical cord mesenchymal stem cells and the 30th generation immortalized human umbilical cord mesenchymal stem cells with good growth status and 90% fusion degree, discard the culture medium, and add an appropriate amount of PBS to rinse the cells twice. Discard the PBS, add trypsin to completely cover the cells, digest for 30s-1min, and add serum-containing culture medium to terminate the digestion when the cells become round and shiny. Transfer the digested cells to a centrifuge tube, centrifuge at 1100rmp / min for 4min, discard the supernatant, resuspend the cells with culture medium, and take an appropriate amount of cells for counting. Inoculate into a six-well plate at a density of 500 cells per well. Culture in a cell culture incubator at 37°C and 5% CO2 for 14 days. When visible clones appear in the culture dish, discard the culture medium, wash twice with PBS, add methanol to fix for 20min, discard methanol, and stain with 0.1% crystal violet stain for 10min. Wash off the crystal violet stain with PBS, count the number of clones larger than 50 cells by naked eye or under a microscope, and the results are as follows Fig. 9 As shown, A and B are normal human umbilical cord mesenchymal stem cells of the 5th generation, and C and D are immortalized human umbilical cord mesenchymal stem cells of the 30th generation. B and D are cell colonies observed under a microscope (X5 magnification). It can be seen that the number of colonies of normal human umbilical cord mesenchymal stem cells of the 5th generation is significantly less than that of immortalized human umbilical cord mesenchymal stem cells of the 30th generation, and the colonies are smaller, with a colony formation rate of about 10%, and the colony formation rate of irreversibly immortalized human umbilical cord mesenchymal stem cells is about 50%.

[0061] Example 7: Growth experiment of immortalized human umbilical cord mesenchymal stem cells.

[0062] Take the 5th generation normal human umbilical cord mesenchymal stem cells and the 30th generation immortalized human umbilical cord mesenchymal stem cells with good growth status and 90% fusion degree, discard the culture medium, add appropriate amount of PBS to rinse the cells twice. Discard the PBS, add trypsin to completely cover the cells, digest for 30s-1min, and add serum-containing culture medium to terminate the digestion when the cells become round and shiny. Transfer the digested cells to a centrifuge tube, centrifuge at 1100rmp / min for 4min, discard the supernatant, resuspend the cells with culture medium, take a 12-well plate, inoculate 2000 30th generation immortalized human umbilical cord mesenchymal stem cells and 5th generation normal human umbilical cord mesenchymal stem cells in each well, digest one well every day starting from the second day for counting, place in a 37°C, 5% CO2 cell culture incubator for 8 consecutive days, draw a growth curve, and the results are as follows Fig.10 As shown in the figure, it can be seen from the growth curve that the 30th generation irreversibly immortalized human umbilical cord mesenchymal stem cells have been growing faster than the 5th generation human umbilical cord mesenchymal stem cells since the first day. Starting from the 5th day, the 30th generation irreversibly immortalized human umbilical cord mesenchymal stem cells have a significantly faster growth rate than the 5th generation human umbilical cord mesenchymal stem cells. Days 3-5 are the logarithmic growth phase with active proliferation, and then enter the plateau phase. This indicates that irreversibly immortalized human umbilical cord mesenchymal stem cells proliferate more actively than the 5th generation human umbilical cord mesenchymal stem cells.

[0063] Example 8: Osteogenesis experiment of immortalized human umbilical cord mesenchymal stem cells.

[0064] First, prepare a gelatin-coated six-well plate: add an appropriate amount of 0.1% gelatin (enough to cover the surface) to the six-well plate and shake it well, then place it in the clean bench for at least 30 minutes. After coating, remove the gelatin and let the six-well plate dry for later use. Take the 5th generation normal human umbilical cord mesenchymal stem cells and 30th generation immortalized human umbilical cord mesenchymal stem cells in good condition and with a confluence of 80-90% and digest them with trypsin. Count the digested cells and calculate the number of cells to 2x10 4 / cm 2 The cell density is inoculated into a pre-coated six-well plate, 2 mL of culture medium is added, and cultured in a 37°C, 5% CO2 cell culture incubator. When the degree of fusion of immortalized human umbilical cord mesenchymal stem cells reaches 60-70%, the culture medium is aspirated, and the prepared osteogenic induction solution is added. The osteogenic induction solution is changed every 3 days. After 4 weeks of induction, the cells are stained with Alizarin Red according to their morphology and growth. Alizarin Red staining method: After the osteogenic induction differentiation is completed, the osteogenic induction solution is aspirated, the cells are rinsed 1-2 times with PBS, and then 2 mL of 4% formaldehyde solution is added to fix at room temperature for 30 minutes. Aspirate the formaldehyde solution, rinse twice with PBS, and add 1 mL of Alizarin Red for staining for 3-5 minutes. Aspirate Alizarin Red, rinse 2-3 times with PBS, and observe the osteogenic staining effect under a microscope. The results are as follows Fig.11As shown, like the 5th generation normal human umbilical cord mesenchymal stem cells, most of the cells in the experimental group differentiated into osteoblasts that can be stained with Alizarin Red. Figure A is the 30th generation irreversible immortalized human umbilical cord mesenchymal stem cells without the addition of osteoinduction solution; Figure B is the 5th generation normal human umbilical cord mesenchymal stem cells without the addition of osteoinduction solution; Figure C is the 30th generation of irreversible immortalized human umbilical cord mesenchymal stem cells osteogenic induction (X5 times); Figure D is the 5th generation human umbilical cord mesenchymal stem cells osteogenic induction (X5 times).

[0065] Example 9: Adipogenesis induction experiment of immortalized human umbilical cord mesenchymal stem cells.

[0066] The 5th generation normal human umbilical cord mesenchymal stem cells and the 30th generation immortalized human umbilical cord mesenchymal stem cells in good condition and with a confluence of 80-90% were digested with trypsin. The digested cells were counted and counted as 2x10 4 / cm 2 The cell density was inoculated into a six-well plate, 2 mL of culture medium was added, and the plate was cultured in a cell culture incubator at 37°C and 5% CO2. When the cell confluence reached 100%, the culture medium was aspirated and 2 mL of adipogenic induction solution A was added. After 3 days of induction, the adipogenic induction solution A was aspirated and 2 mL of adipogenic induction solution B was added. After 24 hours, the adipogenic induction solution B was aspirated and replaced with adipogenic induction solution A. After alternating adipogenic induction solution A and solution B for 5 times, the adipogenic induction solution B was continued to be used for one week until the lipid droplets become large enough and round. Oil Red O staining: After the adipogenic induction differentiation is completed, the adipogenic induction solution was aspirated, the cells were rinsed 1-2 times with PBS, and then 2 mL of 4% formaldehyde solution was added to fix at room temperature for 30 minutes. The formaldehyde solution was aspirated, the cells were rinsed twice with PBS, and 1 mL of Oil Red O working solution (see the previous article for the formula) was added to stain for 30 minutes. The Oil Red O working solution was aspirated, the cells were rinsed 2-3 times with PBS, and the osteogenic staining effect was observed under a microscope. The results are as follows Fig.12 As shown: A is the 5th generation normal human umbilical cord mesenchymal stem cells without the addition of fat induction solution; B is the 30th generation irreversibly immortalized human umbilical cord mesenchymal stem cells without the addition of fat induction solution; C is the 5th generation normal human umbilical cord immortalized mesenchymal stem cells induced into adipogenesis; D is the 30th generation irreversibly immortalized human umbilical cord mesenchymal stem cells induced into adipogenesis. The cells in the experimental group differentiated into adipocytes that can be stained with Oil Red O; the above results prove that the cells we constructed have multidirectional differentiation ability; E is a fluorescence microscope observation under the same field of view as D, indicating that the irreversibly immortalized human umbilical cord mesenchymal stem cells with green fluorescent protein can still see green fluorescence after cell induction differentiation, and have good tracing ability.

[0067] Example 10: Soft agar plate experiment.

[0068] Prepare 1.2% and 0.7% agar (Agarose plus distilled water) in advance, sterilize by high pressure and store in a refrigerator at 4°C. Heat and melt in a microwave or oven on the day of plating and place in a 37°C incubator.

[0069] Lay the bottom layer of gel: Mix 1.2% Agarose and low-glucose DMEM stem cell culture medium in a ratio of 1:1, take 2 mL of the mixture in each well of a 6-well plate, and wait for cooling and solidification at room temperature. Take P5 generation 293T cells in the logarithmic growth phase, P5 generation normal human umbilical cord mesenchymal stem cells, and P30 generation immortalized human umbilical cord mesenchymal stem cells, digest them into single cell suspensions, and adjust the cell number to 5x 10 after counting. 4 / mL.

[0070] Lay the top layer of gel: Mix 0.7% Agarose and cell culture medium in a 1:1 ratio, take 2 mL of the mixture into an EP tube, add 10-20 μL of cell suspension into the tube, which are P5 generation 293T cell wells, P5 generation normal human umbilical cord mesenchymal stem cells, P30 generation immortalized human umbilical cord mesenchymal stem cells, P5 generation normal human umbilical cord mesenchymal stem cells without agar, and P30 generation irreversibly immortalized human umbilical cord mesenchymal stem cells. After fully mixing, add to the 6-well plate with the bottom layer of gel. After the top layer of agar solidifies, place it in a 37°C incubator for 2 weeks, and add 200 μL of culture medium to the 6-well plate every three days.

[0071] The soft agar cell colony formation assay is a common experimental method designed to simulate the semi-solid growth environment of the extracellular matrix in vivo and to conduct in vitro detection and evaluation of the growth potential of pure cell colonies. Tumor cells can proliferate indefinitely and show strong cloning ability, while mature and differentiated cells and mesenchymal stem cells cannot form colonies. In this experiment, immortalized human umbilical cord mesenchymal stem cells had no ability to form colonies in soft agar medium, indicating that they were not tumorigenic. The detailed results are as follows: Fig.13 As shown:

[0072] A is the irreversibly immortalized human umbilical cord mesenchymal stem cells of generation P30 cultured in low-glucose DMEM medium for 12 days (X5 times microscope). The picture under green fluorescent microscope shows that the cells form many clones;

[0073] B is the P5 normal human umbilical cord mesenchymal stem cells cultured in low-glucose DMEM medium for 12 days (X5 magnification), showing that the cells formed clones;

[0074] C is a green fluorescence image of irreversibly immortalized human umbilical cord mesenchymal stem cells at generation P30 cultured in soft agar medium for 12 days (X5 magnification). It shows that no cell clones can be formed in the soft agar, and no colony formation is observed. The soft agar plate has poor transparency, but green fluorescence can still be seen.

[0075] D is the fifth generation of normal human umbilical cord mesenchymal stem cells cultured in soft agar medium for 12 days (X5 magnification). The picture shows that the cells did not form clones and colonies were not observed.

[0076] E is a picture of P5 293T cells cultured in soft agar medium for 12 days (X5 times microscope) showing that the cells formed clones.

[0077] Example 11: Cell karyotype analysis.

[0078] Take well-growing P30 immortalized human umbilical cord mesenchymal stem cells and treat them with 0.1mg / L colchicine for 2h. After routine digestion and centrifugation, 0.075mol / L KCl was used for hypotonic treatment, and freshly prepared methanol / ice ethanol (3:1) predetermined solution was added. After mixing, centrifugation was performed at 800r / min for 10min; the supernatant was discarded, and freshly prepared methanol / ice acetic acid (3:2) fixative was added. Fixation was performed at room temperature for 30min, and the fixation was repeated 3 times. The supernatant was discarded, the cell pellet was resuspended, and smears were made and Gimesa staining was performed. The results are as follows: Fig.14 As shown, A is the karyotype analysis of normal human umbilical cord mesenchymal stem cells of generation P5; B is the karyotype analysis of immortalized human umbilical cord mesenchymal stem cells of generation P30. It can be seen from the figure that immortalized human umbilical cord mesenchymal stem cells of generation P30 have 23 pairs of chromosomes, just like normal human umbilical cord mesenchymal stem cells of generation P5. Karyotype analysis found that they contain sex chromosomes and are still diploid cells. The number and structure of chromosomes are normal, and no aberrations such as deletion, breakage, and ectopicity are found.

[0079] The present invention provides the above embodiments only to illustrate rather than limit the technical solutions of the present invention. Although the above embodiments describe the present invention in detail, relevant technical personnel in the field should understand that the present invention can be modified or equivalently replaced, but any modification and partial replacement that does not depart from the spirit and scope of the present invention should be included in the scope of the claims of the present invention.

Claims

1. A method for constructing immortalized human umbilical cord mesenchymal stem cells, characterized in that: The method first obtains human umbilical cord and digests it to obtain primary human umbilical cord mesenchymal stem cells, which are then subcultured; at the same time, a lentiviral recombinant plasmid carrying an SV40 promoter, an hTERT gene and an EGFP gene is synthesized, the lentiviral recombinant plasmid is packaged and transfected to obtain umbilical cord mesenchymal stem cells, and the successfully transfected umbilical cord mesenchymal stem cells are screened to obtain the finished product.

2. The method for constructing immortalized human umbilical cord mesenchymal stem cells according to claim 1, characterized in that: It includes the following details step: Step S1, obtaining a fresh umbilical cord under sterile conditions, removing the outer membrane and blood vessels, cleaning and cutting into small tissue blocks, cleaning again, sequentially performing a first trypsin digestion, type II collagenase digestion and a second trypsin digestion, centrifuging and discarding the supernatant, resuspending the precipitate in DMEM culture medium, filtering with a 200-mesh sieve, collecting the tissue blocks and the filtrate respectively, repeatedly performing type II collagenase and a second trypsin digestion on the tissue blocks for multiple times, collecting and mixing the filtrate obtained by multiple digestions to obtain primary human umbilical cord mesenchymal stem cell fluid, and performing primary culture and subculture; Step S2, synthesizing a lentiviral recombinant plasmid carrying the SV40 promoter, hTERT gene and EGFP gene; Step S3, culturing 293T cells, mixing Lipofectamine 2000, lentiviral recombinant plasmid and packaging plasmid, co-transfecting 293T cells, continuing to culture 293T cells after transfection and collecting virus liquid secreted by 293T cells, filtering by low-speed centrifugation to remove large particle impurities in the virus liquid, collecting virus precipitate by high-speed centrifugation, and resuspending the virus precipitate to obtain virus suspension; Step S4, obtaining P3 generation umbilical cord mesenchymal stem cells from step S1, adding polybrene and the virus suspension prepared in step S3, continuing to culture the umbilical cord mesenchymal stem cells with DMEM low-glucose medium for transfection, and proliferating the transfected umbilical cord mesenchymal stem cells. When the proliferation culture reaches a cell density of more than 90%, adding a screening medium for screening culture, and the surviving cells after screening culture are the finished product.

3. The method for constructing immortalized human umbilical cord mesenchymal stem cells according to claim 2, characterized in that: The lentiviral recombinant plasmid is pLV[Exp]-EF1A>hTERT-SV40>EGFP:T2A:Puro; the screening culture medium is a complete culture medium containing puromycin, and the concentration of puromycin is 0.4 μg / mL.

4. The method for constructing immortalized human umbilical cord mesenchymal stem cells according to claim 2, characterized in that: The packaging plasmid includes pLP-VSVG plasmid and pPAX2 plasmid, and the mass ratio of pLP-VSVG plasmid, pPAX2 plasmid and lentiviral recombinant plasmid is 1:2:

3.

5. The method for constructing immortalized human umbilical cord mesenchymal stem cells according to claim 2, characterized in that: The cleaning in step S1 is performed by using phosphate buffered saline (PBS); the first trypsin digestion is to add 1.25 g / L trypsin to the small tissue block, digest it in a CO2 incubator for 20 minutes, and then add fetal bovine serum to terminate the digestion; the type II collagenase digestion is to add 0.075% type II collagenase at a volume ratio of 1:8, seal it and place it in a 37°C water bath for oscillation digestion for 1 hour; the second trypsin digestion is to add 1.25 g / L trypsin and digest it in a 37°C water bath for 30 minutes, shaking it once every 10 minutes.

6. The method for constructing immortalized human umbilical cord mesenchymal stem cells according to claim 2, characterized in that: After the second trypsin digestion in step S1 is completed, the mixture is centrifuged at 1100 r / min for 10 min, the precipitate is washed with phosphate buffered saline (PBS) and then centrifuged at 1100 r / min for 10 min to separate the precipitate and the supernatant, and the precipitate is resuspended in a low-glucose DMEM culture medium.

7. The method for constructing immortalized human umbilical cord mesenchymal stem cells according to claim 2, characterized in that: In the step S1, a DMEM culture medium containing 10% fetal bovine serum by volume is used, wherein the DMEM culture medium contains 100 U / mL penicillin and 100 U / mL streptomycin; the subculture is carried out in a CO2 incubator, the culture medium is changed every 3 days, and the cells are subcultured at a ratio of 1:3 after the cell density reaches 80%.

8. The method for constructing immortalized human umbilical cord mesenchymal stem cells according to claim 2, characterized in that: In step S3, 293T cells are cultured until the cell density reaches 80-90% before transfection; the low-speed centrifugation is first centrifuged at 1100 rpm for 5 minutes and then filtered with a 0.22 μm filter; the high-speed centrifugation is centrifuged at 25000 rpm and 4° C. for 90 minutes.

9. The method for constructing immortalized human umbilical cord mesenchymal stem cells according to claim 2, characterized in that: The specific operation of transfection in step S4 is to take umbilical cord mesenchymal stem cells and culture them in DMEM low-glucose medium for proliferation, count 5000 cells and then re-inoculate them into a 48-well culture plate at a seeding density of 5×10 4 cells / 100 μL / well, then add the virus suspension and polybrene to make the final concentration of 2 μg / mL for transfection. After transfection, centrifuge at 1100 r / min for 60 min at room temperature, take the precipitated cells and shake them evenly for proliferation culture.

Citation Information

Patent Citations

  • Human bone marrow mesenchymal stem cell immortalization method

    CN116855540A

Cited By

  • Engineered mitochondria as well as preparation method and application thereof

    CN120227353A